Developer docs
API playgroundTry for free, no card

Search company profiles

Aurore Life Sciences

Full company profile

uuid000x9am

Namestring
Aurore Life Sciences
Legal namestring
Aurore Life Sciences
Websiteurl
aurorels.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Aurore Life Sciences is a privately held, pure-play Active Pharmaceutical Ingredient (API) and intermediates manufacturer headquartered in Hyderabad, India. Founded in 2017, the company operates two manufacturing facilities — the USFDA- and EU-approved Jeedimetla site (approximately 450 KL reactor capacity, five manufacturing blocks, fifteen clean rooms) and the WHO-GMP- and EU-WC-certified Kazhipally greenfield site (approximately 390 KL capacity, three blocks, four clean rooms) — for a combined 840 KL of reactor capacity and 19 clean rooms. Aurore manufactures 76+ APIs across therapeutic categories including antivirals, anti-hypertensives, anti-diabetics, anti-inflammatory, anti-psychotics, anti-coagulants, anti-retrovirals, and cardiovascular drugs, and supports this portfolio with in-house key starting material and intermediate production.

The company's core technology is chemical synthesis and semi-synthesis of APIs with full backward integration from key starting materials to finished APIs, supplemented by specialty capabilities such as cryogenic reactions (used in Dapagliflozin and Empagliflozin manufacturing). R&D and quality infrastructure comprises 60 R&D scientists, 65 analytical experts, and 10 doctorates working with UHPLC, NMR, mass spectrometry, and X-ray crystallography. The regulated product portfolio is backed by 35+ US Drug Master Files, 30+ Certificates of Suitability to the European Pharmacopoeia, and management systems certified to ISO 9001, ISO 14001, and ISO 45001.

Aurore generates revenue through two streams: merchant supply of APIs and intermediates to global formulation manufacturers (quote-based, contract and commercial volumes), and Contract Development and Manufacturing Organization (CDMO) services covering new chemical entities, advanced intermediates, high-potency drugs, and controlled substances from R&D through commercial manufacturing. Customers are global pharmaceutical manufacturers across 22+ countries in North America, Europe, Asia Pacific, the Middle East, Africa, South America, and Oceania; customer logos are not disclosed. The go-to-market is B2B enterprise field sales with direct engagement rather than distributor-led channel activity.

Short descriptiontext

Aurore Life Sciences is a Hyderabad, India-based, privately held API and intermediates manufacturer operating two USFDA- and EU-approved plants (840 KL combined capacity) to supply 76+ APIs across multiple therapeutic categories and provide CDMO services to global pharmaceutical clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, active pharmaceutical ingredients, CDMO services, drug intermediates, API production
Industry5 codes
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAD
Controlled Substances / DEA-Scheduled API Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Services-Commercial Physical & Biological Research8731
Product category
Active Pharmaceutical Ingredients (API) Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1API & Intermediates Manufacturing
TypeOne Time License
Description

Revenue from manufacturing and selling Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates to global pharmaceutical companies on a contract and commercial basis.

aurorels.com
2CDMO Services
TypeProfessional Services
Description

Contract Development and Manufacturing Organization (CDMO) services providing end-to-end solutions from R&D through commercial manufacturing for pharmaceutical clients.

aurorels.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aurore Life Sciences manufactures Active Pharmaceutical Ingredients (APIs) and intermediates, and provides Contract Development and Manufacturing Organization (CDMO) services to global pharmaceutical companies. The company develops and produces high-quality drug substances and key starting materials, supporting formulation development and commercial-scale manufacturing for the pharmaceutical industry.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 2 USFDA & EU Approved Facilities
+2 more records
Product overview1 text field

Aurore Life Sciences is a pure-play API and intermediates manufacturing company driven by R&D excellence with seamless backward integration. The company offers a comprehensive portfolio of 76+ Active Pharmaceutical Ingredients (APIs) across therapeutic categories including antivirals, anti-hypertensives, anti-diabetics, anti-inflammatory, anti-psychotics, anti-coagulants, anti-retrovirals, and cardiovascular drugs. The product portfolio is organized into three main categories: (1) APIs as the core product offering with 35+ USDMFs and 30+ CEPs, (2) pharmaceutical intermediates supporting backward integration for API manufacturing, and (3) CDMO services for contract development and manufacturing of new chemical entities, advanced intermediates, high-potency drugs, and controlled substances.

Product and service3 records
1Active Pharmaceutical Ingredients (APIs)
CategoryAPI Manufacturing
Description

Manufacture of Active Pharmaceutical Ingredients (drug substances) that provide therapeutic effect in finished pharmaceutical formulations. These APIs are produced for pharmaceutical formulators and global generic and innovator drug manufacturers at commercial scale.

2Pharmaceutical Intermediates
CategoryAPI Manufacturing
Description

Manufacture of drug intermediates and key starting materials used as precursors in the synthesis of Active Pharmaceutical Ingredients. Offered to pharmaceutical companies requiring high-purity chemical intermediates for their API production processes.

3CDMO Services
CategoryContract Manufacturing Services
Description

Contract Development and Manufacturing Organization services covering process development, scale-up, and contract manufacturing of APIs and intermediates for pharmaceutical clients seeking custom development and production support.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian API and intermediates manufacturer with strong backward integration and a CDMO segment serving global pharma. Highly comparable to Aurore on product model, customer base, and India-based manufacturing footprint, though at substantially larger scale.

TypeDirect peer
Description

Indian manufacturer of APIs and intermediates across therapeutic categories including anti-diabetic, cardiovascular, and anti-inflammatory. Comparable on product model and global B2B customer base, though smaller and less CDMO-focused.

TypeDirect peer
Description

Indian CRAMS/CDMO company focused on API development and manufacturing for global pharma. Directly comparable on contract API manufacturing model, backward integration, and USFDA-aligned operations.

TypeDirect peer
Description

Global CDMO offering integrated API and drug product development services, including high-potency and complex synthesis. Comparable to Aurore on CDMO positioning and complex chemistry capabilities.

TypeBroad incumbent
Description

Large Indian pharmaceutical company with a substantial API manufacturing business alongside finished formulations. Overlaps with Aurore on API/intermediates production and USFDA-approved manufacturing, but operates at much greater scale across the full pharma value chain.

TypeDirect peer
Description

Indian CDMO providing API development, manufacturing, and analytical services to global innovator and generic pharma. Comparable on CDMO service model, technical complexity, and customer base.

TypeEmerging player
Description

Indian pharmaceutical company with API manufacturing operations supporting its finished-dose formulation business. Comparable on API/intermediate manufacturing and USFDA exposure, though more formulation-integrated than Aurore.

TypeBroad incumbent
Description

India-based pharma company with API and CDMO operations across multiple therapeutic categories. Comparable on API manufacturing and CDMO services, but with broader portfolio including radiopharma and dosage forms.

TypeDirect peer
Description

Indian-headquartered API manufacturer and CDMO offering API, intermediates, and formulation services globally. Directly comparable on therapeutic-area breadth, regulatory filings (USDMFs/CEPs), and CDMO exposure.

10Syngene International
TypeDirect peer
Description

Indian CRO/CDMO offering API development, manufacturing, and integrated discovery services to global pharma. Comparable on contract manufacturing model, India-based operations, and high-end chemistry capabilities including cryogenic and high-potency handling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aurore Life Sciences

Active Pharmaceutical Ingredients (API) Manufacturingaurorels.com

Aurore Life Sciences is a Hyderabad, India-based, privately held API and intermediates manufacturer operating two USFDA- and EU-approved plants (840 KL combined capacity) to supply 76+ APIs across multiple therapeutic categories and provide CDMO services to global pharmaceutical clients.

What Aurore Life Sciences does

Aurore Life Sciences is a privately held, pure-play Active Pharmaceutical Ingredient (API) and intermediates manufacturer headquartered in Hyderabad, India. Founded in 2017, the company operates two manufacturing facilities — the USFDA- and EU-approved Jeedimetla site (approximately 450 KL reactor capacity, five manufacturing blocks, fifteen clean rooms) and the WHO-GMP- and EU-WC-certified Kazhipally greenfield site (approximately 390 KL capacity, three blocks, four clean rooms) — for a combined 840 KL of reactor capacity and 19 clean rooms. Aurore manufactures 76+ APIs across therapeutic categories including antivirals, anti-hypertensives, anti-diabetics, anti-inflammatory, anti-psychotics, anti-coagulants, anti-retrovirals, and cardiovascular drugs, and supports this portfolio with in-house key starting material and intermediate production.

The company's core technology is chemical synthesis and semi-synthesis of APIs with full backward integration from key starting materials to finished APIs, supplemented by specialty capabilities such as cryogenic reactions (used in Dapagliflozin and Empagliflozin manufacturing). R&D and quality infrastructure comprises 60 R&D scientists, 65 analytical experts, and 10 doctorates working with UHPLC, NMR, mass spectrometry, and X-ray crystallography. The regulated product portfolio is backed by 35+ US Drug Master Files, 30+ Certificates of Suitability to the European Pharmacopoeia, and management systems certified to ISO 9001, ISO 14001, and ISO 45001.

Aurore generates revenue through two streams: merchant supply of APIs and intermediates to global formulation manufacturers (quote-based, contract and commercial volumes), and Contract Development and Manufacturing Organization (CDMO) services covering new chemical entities, advanced intermediates, high-potency drugs, and controlled substances from R&D through commercial manufacturing. Customers are global pharmaceutical manufacturers across 22+ countries in North America, Europe, Asia Pacific, the Middle East, Africa, South America, and Oceania; customer logos are not disclosed. The go-to-market is B2B enterprise field sales with direct engagement rather than distributor-led channel activity.

Aurore Life Sciences firmographics

Firmographics
Name
Aurore Life Sciences
Legal name
Aurore Life Sciences
Website
https://aurorels.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
251–500 employees
Short description
Aurore Life Sciences is a Hyderabad, India-based, privately held API and intermediates manufacturer operating two USFDA- and EU-approved plants (840 KL combined capacity) to supply 76+ APIs across multiple therapeutic categories and provide CDMO services to global pharmaceutical clients.
Ownership category
akta.pro rank

Aurore Life Sciences industry classification

Industry
Product category
Active Pharmaceutical Ingredients (API) Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAD
Controlled Substances / DEA-Scheduled API Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Pharmaceutical manufacturing
  • Active pharmaceutical ingredients
  • CDMO services
  • Drug intermediates
  • API production

Where Aurore Life Sciences is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices3 records

Markets served

Aurore Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure

Revenue model

  1. API & Intermediates Manufacturing: Revenue from manufacturing and selling Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates to global pharmaceutical companies on a contract and commercial basis.
  2. CDMO Services: Contract Development and Manufacturing Organization (CDMO) services providing end-to-end solutions from R&D through commercial manufacturing for pharmaceutical clients.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Aurore Life Sciences product offering

Product offering

Core offering

Aurore Life Sciences manufactures Active Pharmaceutical Ingredients (APIs) and intermediates, and provides Contract Development and Manufacturing Organization (CDMO) services to global pharmaceutical companies. The company develops and produces high-quality drug substances and key starting materials, supporting formulation development and commercial-scale manufacturing for the pharmaceutical industry.

Product overview

Aurore Life Sciences is a pure-play API and intermediates manufacturing company driven by R&D excellence with seamless backward integration. The company offers a comprehensive portfolio of 76+ Active Pharmaceutical Ingredients (APIs) across therapeutic categories including antivirals, anti-hypertensives, anti-diabetics, anti-inflammatory, anti-psychotics, anti-coagulants, anti-retrovirals, and cardiovascular drugs. The product portfolio is organized into three main categories: (1) APIs as the core product offering with 35+ USDMFs and 30+ CEPs, (2) pharmaceutical intermediates supporting backward integration for API manufacturing, and (3) CDMO services for contract development and manufacturing of new chemical entities, advanced intermediates, high-potency drugs, and controlled substances.

Differentiator

Problem solved

Functional benefit

Products and services

  • Active Pharmaceutical Ingredients (APIs) Manufacture of Active Pharmaceutical Ingredients (drug substances) that provide therapeutic effect in finished pharmaceutical formulations. These APIs are produced for pharmaceutical formulators and global generic and innovator drug manufacturers at commercial scale.
  • Pharmaceutical Intermediates Manufacture of drug intermediates and key starting materials used as precursors in the synthesis of Active Pharmaceutical Ingredients. Offered to pharmaceutical companies requiring high-purity chemical intermediates for their API production processes.
  • CDMO Services Contract Development and Manufacturing Organization services covering process development, scale-up, and contract manufacturing of APIs and intermediates for pharmaceutical clients seeking custom development and production support.

Quantifiable outcome

  • 2 USFDA & EU Approved Facilities
  • +2 more outcomes

Companies that use Aurore Life Sciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Aurore Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Aurore Life Sciences partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Aurore Life Sciences competitors and assessment

Company assessment

Direct peers

  • Divi's Laboratories: Indian API and intermediates manufacturer with strong backward integration and a CDMO segment serving global pharma. Highly comparable to Aurore on product model, customer base, and India-based manufacturing footprint, though at substantially larger scale.
  • Aarti Drugs: Indian manufacturer of APIs and intermediates across therapeutic categories including anti-diabetic, cardiovascular, and anti-inflammatory. Comparable on product model and global B2B customer base, though smaller and less CDMO-focused.
  • Suven Pharmaceuticals: Indian CRAMS/CDMO company focused on API development and manufacturing for global pharma. Directly comparable on contract API manufacturing model, backward integration, and USFDA-aligned operations.
  • Piramal Pharma Solutions: Global CDMO offering integrated API and drug product development services, including high-potency and complex synthesis. Comparable to Aurore on CDMO positioning and complex chemistry capabilities.
  • Sai Life Sciences: Indian CDMO providing API development, manufacturing, and analytical services to global innovator and generic pharma. Comparable on CDMO service model, technical complexity, and customer base.
  • Laurus Labs: Indian-headquartered API manufacturer and CDMO offering API, intermediates, and formulation services globally. Directly comparable on therapeutic-area breadth, regulatory filings (USDMFs/CEPs), and CDMO exposure.
  • Syngene International: Indian CRO/CDMO offering API development, manufacturing, and integrated discovery services to global pharma. Comparable on contract manufacturing model, India-based operations, and high-end chemistry capabilities including cryogenic and high-potency handling.

Broad incumbents

  • Aurobindo Pharma: Large Indian pharmaceutical company with a substantial API manufacturing business alongside finished formulations. Overlaps with Aurore on API/intermediates production and USFDA-approved manufacturing, but operates at much greater scale across the full pharma value chain.
  • Jubilant Pharmova: India-based pharma company with API and CDMO operations across multiple therapeutic categories. Comparable on API manufacturing and CDMO services, but with broader portfolio including radiopharma and dosage forms.

Emerging players

  • Granules India: Indian pharmaceutical company with API manufacturing operations supporting its finished-dose formulation business. Comparable on API/intermediate manufacturing and USFDA exposure, though more formulation-integrated than Aurore.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Aurore Life Sciences social profiles

Digital presence

Aurore Life Sciences compliance and trust

Trust signal

Compliance9 records

Aurore Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aurore Life Sciences leadership team

Management profile

Number of profiles

Profiles1 record

Aurore Life Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Aurore Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aurore Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aurore Life Sciences

What does Aurore Life Sciences do?

Aurore Life Sciences manufactures Active Pharmaceutical Ingredients (APIs) and intermediates, and provides Contract Development and Manufacturing Organization (CDMO) services to global pharmaceutical companies. The company develops and produces high-quality drug substances and key starting materials, supporting formulation development and commercial-scale manufacturing for the pharmaceutical industry.

Is Aurore Life Sciences a public or private company?

Aurore Life Sciences is a private company. It is classified as unknown and is currently operating.

When was Aurore Life Sciences founded?

Aurore Life Sciences was founded in 2017. It employs 251 to 500 people.

Where is Aurore Life Sciences based?

Aurore Life Sciences is headquartered in Hyderabad, India, in the Asia region.

How does Aurore Life Sciences make money?

Two revenue lines are on record. API & Intermediates Manufacturing is the primary driver. The others are CDMO Services.

Who are Aurore Life Sciences's main competitors?

Direct peers on record are Divi's Laboratories, Aarti Drugs, Suven Pharmaceuticals, Piramal Pharma Solutions, Sai Life Sciences, Laurus Labs and Syngene International. Broad incumbents are Aurobindo Pharma and Jubilant Pharmova. Granules India is listed as an emerging player.

Does Aurore Life Sciences have an API?

No public API is recorded for Aurore Life Sciences.

What industry is Aurore Life Sciences in?

Aurore Life Sciences's product category is Active Pharmaceutical Ingredients (API) Manufacturing. Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 32541 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales